This trial is testing GSK2857916 combined with Pembrolizumab in patients with relapsed/refractory myeloma. Researchers are studying whether these drugs work in myeloma, are safe, and what doses work best.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
A subject will NOT be eligible for inclusion in this study if any of the following criteria apply:
August 04, 2021
GSK recognises that there may be circumstances when it is appropriate for Healthcare Professionals to give their patients Investigational medicines to treat life threatening or seriously debilitating diseases/conditions where no satisfactory alternatives exist.
Read the latest news and updates on this trial.
July 14, 2020
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.
January 21, 2020
March 21, 2019
Median progression-free survival extends to twelve months